Fibromyalgia: Market View, Current and Future Competitive Landscape
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This reports provides a data-driven overview of the current and future competitive landscape in Fibromyalgia Therapeutics._x000D_
_x000D_
• In 2024 and 2029, India is anticipated to have the highest number of diagnosed prevalent cases of fibromyalgia, representing a large portion of global cases._x000D_
• Currently, the fibromyalgia treatment landscape has a limited number of approved drugs and is saturated with generics._x000D_
• Fibromyalgia’s pipeline is relatively thin, skewed toward Phase I–II investigational assets with no presence of late-stage molecules._x000D_
• Over the past decade, 243 clinical trials have been conducted in fibromyalgia. The year with the most studies initiated was 2021, with 46 trials, followed by 2022 with 27 trials. _x000D_
• During the past 24 months, seven mergers and acquisitions and two strategic alliances involving companies developing fibromyalgia assets were completed. _x000D_
• The fibromyalgia market is not likely to see any major shifts in the near term, with no products in pre-registration or Phase III development.
Scope
GlobalData’s Fibromyalgia: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. _x000D_
_x000D_
Components of the report include:_x000D_
• Disease Landscape_x000D_
• Disease Overview_x000D_
• Epidemiology Overview_x000D_
• Treatment Overview_x000D_
• Marketed Products Assessment_x000D_
• Breakdown by Mechanism of Action, Route of Administration_x000D_
• Product Profiles with Sales Forecast_x000D_
• Pricing and Reimbursement Assessment_x000D_
• Annual Therapy Cost_x000D_
• Time to Pricing and Time to Reimbursement_x000D_
• Pipeline Assessment_x000D_
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration_x000D_
• Product Profiles with Sales Forecast_x000D_
• Late-to-mid-stage Pipeline Drugs_x000D_
• Phase Transition Success Rate and Likelihood of Approval_x000D_
• Clinical Trials Assessment_x000D_
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status_x000D_
• Enrolment Analytics, Site Analytics, Feasibility Analysis_x000D_
• Deals Landscape_x000D_
• Mergers, Acquisitions, and Strategic Alliances by Region_x000D_
• Overview of Recent Deals_x000D_
• Commercial Assessment_x000D_
• Key Market Players_x000D_
• Future Market Catalysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the Fibromyalgia Therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Fibromyalgia Therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Fibromyalgia (Fibromyalgia Syndrome) reports